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IL-2, initially discovered for its mitogenic activity on T cells (1), also acts on mono-
cytes (2) . T and B cells express at least two forms of IL-2 receptor (IL-2R) : the p55
glycoprotein (IL-2Rtx), which is recognized by the anti-TacmAb (3), and the p70-75
kD glycoprotein (IL-2RO), which reacts with the TU27 mAb (4) . The p55 chain
binds IL-2 with a low affinity (Kd ti10-g M), the p70-75 chain binds IL-2 with an
intermediate affinity (Kd N10'9 M), and both molecules form a noncovalently linked
heterodimer that binds IL-2 with high affinity (Kd _10-12 M) . The response ofT
orB cells to IL-2 seems to be mediated by p70-75 and notp55 (5, 6) . Human mono-
cytes respond to IL-2 with induction of IL-1mRNA (7), development oftumoricidal
activity (2), and we have recently shown that IL-2 enhances c-fms mRNA expres-
sion (Espinoza-Delgado et al., manuscript submitted) . The ability ofhumanmono-
cytes to respond to IL-2 indicates the presence of a functional receptor for IL-2 on
these cells . However, fresh human monocytes do not express Tac antigen (8), and
there are no reports concerning the expression of p70-75 on fresh or IL-2-treated
monocytes . We have investigated the surface expression ofp70-75, and its potential
role in the cytotoxic response of monocytes to IL-2, using the anti-p75 mAb TU27
(4) . We demonstrated that human monocytes express constitutively high levels of
p75 and that TU27 mAb blocks the activation to a cytolytic stage induced by IL-2
but does not block IFN-y-induced, monocyte-mediated cytolysis .
Materials and Methods
Cell Culture.
￿
Monocytes were purified from leukophoresed PBMC by centrifugal elutria-
tion (9) . The purity of the monocyte preparation used in these studies was 93 t 3% as as-
sessed by morphology on Giemsa-stained cytocentrifuge preparations and flow cytometry
using the monocyte-specific mAb Leu M3 . Cells were cultured in RPMI 1640 (Advanced
Biotechnology, Inc ., Columbia, MD), containing penicillin 100 U/ml, streptomycin 100 Ag/ml,
2MM t.-glutamine, 20mM Hepes (Gibco Laboratories, Grand Island, NY) and 10% heat-
inactivatedFCS (HyClone Laboratories, Logan, UT) . Recombinanthuman IL-2 was kindly
provided by Cetus Corp ., Emeryville, CA . Recombinant human IFN-y was kindly provided
by Genentech, Inc ., South San Francisco, CA . LPS levels were less than 12 pg/ml in all re-
agents and media used .
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Monoclonal Antibodies.
￿
AntiTacmAb was provided byDr. T. Waldmann, NIH, Bethesda,
MD . Anti-p75 (TU27) mAb was provided by Dr. T. Takeshita, Tohoka University School
of Medicine, Sendai, Japan . Antimonocyte differentiation antigen Leu M3 mAb and anti-T
cell CD3 mAb were purchased from commercial sources (Becton Dickinson & Co., Moun-
tain View, CA) . Anti-IFN-y mAb mouse IgGI (k) (1 x 106 IFN-y NU/mg) was provided by
the Biological Resources Branch, BRMP (10) .
Cytotoxicity.
￿
Monocytes were cultured under nonadherent conditions in 96-well round-
bottomed polypropylene microtiter plates (Wilks Precision Instruments, Rockville, MD) .
IL-2 or IFN-y was added into test wells containing monocytes for 24 h and then washed ex-
tensively before adding labeled tumor target cells . HT29, a human colon carcinoma cell line
(American Type Culture Collection, Rockville, MD ; IL-2 units used in this paper are Cetus
units, 1 Cetus unit is equivalent to 6 international units), was used as a target . HT29 cells
were labeled by incubating 5 x 106 tumor cells with 40 uCi "IIndium ("'In) (Amersham
Corp., Arlington Heights, IL) for 15 min at room temperature in 1 ml ofmedium . Triplicate
monocyte cultures were incubated with 5 x 103 labeled target cells at an E/T ratio of 20:1
in 200 pl ofmedium for 48 h . The plates were then centrifuged for 5 min at 350g, and 75,ul
of the culture supernatant were harvested and the radioactivity was measured . The results
were expressed as percentage of "'In released into the medium calculated from the average
cpm of triplicate samples as [(experimental cpm - spontaneous cpm)/(total cpm - sponta-
neous cpm)] x 100 .
Flow Cytometry.
￿
Cells were treated with FITC- or phycoerythrin (PE)-labeled mAbs (Becton
Dickinson & Co., Mountain View, CA) according to the following procedures : 5 x 105 cells
were incubated with 20 Al ofthe appropriate dilution ofmAb in 0 .1 ml ofPBS supplemented
with 2% human AB serum and 0.1% sodium azide (Gibco) for 30 min at 4°C . Samples of
20,000 cells were analyzed on a FACScan Flow Cytometer.
Results
The expression of p55 and p75 proteins in fresh human monocytes (92% Leu
M3+ , CD3- ; range 90-96% [Fig. 1 B]) from 10 different donors was studied by two-
color flow cytometry When these cells were stained withFITCTU27 and Leu M3-PE
mAbs (Fig. 1 C), nearly all the Leu M3 + cells (93%) expressed p75 protein . In con-
trast, when the monocytes were stained with FITC-labeled antiTac and LeuM3-PE
(Fig . 1 D), none of the monocytes expressed detectable p55 protein .
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FIGURE 1 .
￿
Expression ofIL-2" and IL-2Ra
on fresh monocytes . Monocytes were stained with
FITC- or PE-conjugated mAbs . Contour plots
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ofmonocytes stained with (A) FITC-conjugated
CD3-FITC
￿
IgGI control mAb and PE-conjugated IgG2b
control mAb . (B) CD3-FITC and Leu M3-PE
mAbs ; (C) FITCTU27 (IgGI) and Leu M3-PE
mAbs ; (D) FITC-antiTaC (IgG2a) and Leu M3-
PE mAbs . (a) Decades of a fluorescence loga-
rithmic scale .
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IL-R a-FITCExperiments were performed to determine whether the expression ofp75 wasmodu-
lated during the activation of monocytes to a tumoricidal stage by IFN-'Y or IL-2.
Monocytes were cultured for 24 h in medium alone or supplemented with 1,000
U/ml of IL-2 or 500 U/ml of IFN-y and tested for p55 and p75 expression. Fig.
2 shows the Leu M3 +, CD3- gated flow cytometry histograms of the various mono-
cyte populations. The results (Fig. 2 A) demonstrated that the expression of p75
by monocytes is not influenced by treatment with IL-2 . In contrast, the same mono-
cytes respond to IFN-y but not to IL-2, with a majorincrease in percentage ofp55-
expressing cells (Fig. 2 B).
To study the role ofp55 and p75 in the activation ofmonocytes by IL-2, we exam-
ined the effects of TU27 or antiTac mAbs in the expression of cytotoxic activity.
IFN-y-activated monocytes were used as a specificity control. Under the experimental
conditions used, IL-2 or IFN-y alone induced cytotoxic activity in human mono-
cytes. Dose-response experiments demonstrated that 1,000 U/ml ofIL-2 or 500 U/ml
of IFN-y induced plateau levels of cytotoxicity (data not shown), and these concen-
trations were used in the following experiments. Cells were incubated for 24 h with
increasing concentrations of TU27 or antiTac mAbs with or without IL-2 or IFN-'Y;
cells were then washed and assayed for cytotoxic activity. Depicted in Fig. 3 A is
the result of a representative experiment. IL-2-treated monocytes expressed cyto-
toxic activity (38%) that was not affected by the addition of increasing amounts of
antiTac mAb. In contrast, TU27 mAb caused adose-related decrease ofIL-2-induced
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FIGURE 2.
￿
Expression of IL-2RO and IL-2Ra
on monocytes activated by IL-2 or IFN--y. Mono-
cytes were treated with 1,000 U/ml ofIL-2 or 500
U/ml ofIFN-y for 24 h before staining with mAb.
Histograms of Leu3' monocytes stained with
FITCTU27 (A) or with FITC-antiTac mAb (B).
Medium ( . . .) IL-2 treated with monocytes (... .. .).
IFN-y-treated monocytes (---), relative to CD3-
FITC control antibody (-).
FIGURE 3.
￿
Effects of mAbs on the activation of
monocytes by IL-2 or IFN-y. (A) Elutriated
monocytes were cultured with medium (---) or
1,000 U/ml of IL-2 (-). (B) Monocytes were
cultured with medium (---)or 500 U/ml ofIFN-
y (-). TU27 mAb (O), isotype-matched con-
trol Ig (0), antiTac mAb (EI), anti-IFN-y mAb
(/). (a) Relative concentration of mAbs. 100 is
equal to 100 ug/ml of TU27, isotype-matched
IgG, antiTac, or 2,000 neutralizingU/ml ofanti-
IFN-y mAbs. Monocytes were preincubated with
TU27, antiTac or isotype-matched Ig mAbs for
1 h at 37°C and then activators were added. The
spontaneous release of . . .In from target cells cul-
tured alone was <10% of the total incorporated
radioactivity. All values represent the means of
triplicate determinations. The standard errors
were <10% of the mean.1824
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cytotoxic activity that reached maximum at concentrations of TU27 of 50 Ag/ml.
TU27 mAb alone did not activate monocytes. Anti-IFN-y mAb used as a control
did not affect the induction of cytotoxic activity by IL-2 . These results demonstrate
that anti-p75 but not anti-p55 mAbs block the activation of monocytes by IL-2. To
test whether the inhibitory effects of TU27 were selective for IL-2-induced cytotox-
icity, experiments were done with monocytes activated with IFN-y (Fig. 3 B). TU27
did not affect the activation of monocytes by IFN--y . Under the same conditions
anti-IFN-y mAb at concentrations of 1,000 neutralizing U/ml, substantially decreased
the ability of IFN--y to induce cytotoxicity. These results demonstrate that the in-
hibitory effects of TU27 are restricted to the IL-2-induced monocyte activation.
Discussion
Understanding of the mechanisms by which IL-2 activates monocytes has been
hampered by the lack of information concerning the expression of IL-2R proteins
on these cells. Although p55 can be induced by treatment of monocytes with IFN-'v
(8), we have found that Tac antigen is not expressed on fresh human monocytes,
confirming and extending previous reports. Moreover, we have observed that anti-
Tac mAb does not affect the expression of tumoricidal activity by IL-2-activated
monocytes. Overall these results indicate that the Tac antigen may not be involved
in the activation of monocytes by IL-2 . Using the mAb TU27 that specifically recog-
nizes p75 (4), we demonstrated that a high percentage offresh resting human mono-
cytes expressed p75 protein . To date monocytes from 10 different normal donors
have been tested for p75 expression and more than 90% of such monocytes react
with TU27 in all donors tested.
To examine the role of p75 in human monocyte activation, we investigated the
effects of TU27 mAb on the cytotoxic activity of monocytes induced by IL-2. TU27
inhibited in a dose-dependent manner the activation of monocytes to a tumoricidal
stage by IL-2 . The inhibitory effects of TU27 were not due to a toxic effect since
that mAb did not affect IFN-y-induced cytotoxicity. Moreover, isotype-matched
IgG did not inhibit the activation ofmonocytes by IFN-y or IL-2. Conversely, neu-
tralizing antibodies to IFN-y blocked the activation of monocytes by IFN-'v but not
by IL-2. These results indicate that the activation ofmonocytes cannot be accounted
for by minute amounts of IFN-y that may be released in the medium by the few
nonmonocytic contaminating cells present in the culture. This conclusion is strength-
ened by the observation that IFN-y was never detected by RIA in the supernatant
of IL-2-treated monocytes (data not shown). In conclusion, these results argue against
the possibility that the inhibitory effects of TU27 on monocyte activation by IL-2
may be due to a block of IL-2-induced IFN-y release by contaminating lympho-
cytes. In contrast, our results support the idea that TU27 blocked the biological effects
of IL-2 by interfering with the function of p75 . Significant inhibition of the cyto-
toxic activity requires more than 10 tig/ml ofTU27, a concentration 10 times higher
than that required to saturate the receptor. The differences may be due to internali-
zation and recycling of IL-2Rs occurring during the activation but absent during
FAGS studies performed at 4°C in the presence of NaN3 .
The demonstration of p75 on resting monocytes provides an explanation for the
ability of these cells to respond to IL-2. Constitutive expression of p75 has been de-
tected on CD3 - LGL (NK cells) and it has been shown that the augmentation ofESPINOZA-DELGADO ET AL.
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the cytolytic activity of NK cells and LAK cells by IL-2 can be blocked by TU27
antibodies (11; and Ortaldo, J. R., et al., manuscript submitted for publication). These
results indicate that natural effector cells that respond to IL-2 with antitumor ac-
tivity and cytokine secretion share the constitutive expression of p75, which may
be important for the prompt activation ofthese effector cells during an immune re-
sponse. However, the cellular events that follow the stimulation of the p75
receptor-bearing monocytes by IL-2 are different from the events that follow IL-2
stimulation of p75 receptor-bearing LGL. IL-2 is mitogenic for LGL but not for
monocytes. Thus, the comparison of the molecular events elicited by IL-2 in CD3-
LGL and monocytes may provide important insights on differences in IL-2R bi-
ology in distinct cell lineages.
Summary
We investigated the expression of IL-2R subunits in human monocytes using the
TU27 mAb, which recognizes the p75 chain, and antiTac mAb, which recognizes
the p55 moiety of the IL-2R. We found that p75 but not p55 is constitutively ex-
pressed in more than 90% of fresh human monocytes. Antibody to p75, but not
to p55, inhibited the activation of monocytes to a cytotoxic stage induced by IL-2
but did not block IFN-,y-induced cytotoxicity. Our data demonstrate that the p75
chain is expressed on human monocytes and is involved in the activation of mono-
cytes by IL-2 .
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